Last Updated : May 21, 2019
Details
FilesGeneric Name:
Palbociclib (with Fulvestrant)
Project Status:
Complete
Therapeutic Area:
Palbociclib (Ibrance) in combination with fulvestrant for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer
Manufacturer:
Pfizer Canada Inc.
Brand Name:
Ibrance (with Faslodex)
Project Line:
Reimbursement Review
Project Number:
PC0150-000
NOC Status at Filing:
Post NOC
Strength:
75 mg, 100 mg & 125 mg
Tumour Type:
Breast
Indications:
Advanced or Metastatic Breast Cancer
Funding Request:
In combination with fulvestrant for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer whose disease progressed after prior endocrine therapy, Pre- or perimenopausal women must also be treated with a luteinizing hormone releasing hormone (LHRH) agonist
Sponsor:
Pfizer Canada Inc.
Submission Date:
Submission Deemed Complete:
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
pERC Meeting:
Final Recommendation Issued:
Files
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
Last Updated : May 21, 2019